Colon Cancer Clinical Trial
Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes
Summary
The purpose of this study is to understand the role bacteria that normally live in the colon may play in colorectal cancer risk, in addition to the hereditary risk to colorectal cancer. The investigators will collect stool specimens as well as additional colon biopsy specimens during the patient's scheduled colonoscopy procedure. The investigators will also collect a questionnaire about diet and lifestyle. The samples will be used to study the impact of diet on naturally-occurring oral and gut bacteria and their influences on human health including risk of cancer.
Eligibility Criteria
Inclusion Criteria:
Male or Female age 18 or older
Hereditary colorectal cancer syndrome with one of the following:
Lynch syndrome, as defined by the presence of a deleterious germline mutation in the MLH1, MSH2, MSH6, PMS2 or EPCAM genes
Other hereditary colonic polyposis syndromes, as defined by the presence of a deleterious germline mutation in any one of the following polyposis genes (APC, biallelic MYH, STK11, SMAD4, BMPR1A, or other CRC-risk associated genes at discretion of PI)
Exclusion Criteria:
Unable to provide informed consent for testing
Unable to complete English language questionnaire
Receiving active chemotherapy
Having completed active chemotherapy less then 12 months prior to day of scheduled lower endoscopy
No infectious or drug induced colitis less then 12 months prior to day of scheduled lower endoscopy
No history of inflammatory colitis (Crohn's disease or ulcerative colitis)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10065, United States
How clear is this clinincal trial information?